sNN 0031

Drug Profile

sNN 0031

Alternative Names: rh PDGF-BB; sNN-0031

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroNova AB
  • Developer Newron Pharmaceuticals
  • Class Antiparkinsonians; Nerve growth factors
  • Mechanism of Action Neuron stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 26 Jan 2016 Newron terminates a phase I trial in Parkinson's disease in Sweden (NCT01829867)
  • 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Germany (Intracerebral)
  • 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Sweden (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top